<DOC>
	<DOCNO>NCT01938443</DOCNO>
	<brief_summary>The purpose study assess safety combination treatment GSK2256098 trametinib mesothelioma subject subject select tumor type . Also , study identify maximum tolerate combination dose GSK2256098 trametinib . This study Phase I , open-label , dose-escalation study determine maximal tolerate dose ( MTD ) recommend Phase 2 dose ( RP2D ) regimens oral MEK inhibitor trametinib ( daily [ OD ] dose ) oral FAK inhibitor GSK2256098 ( twice daily [ BID ] dose ) . The synergy combination observe wide range concentration result several-fold reduction compound concentration achieve equivalent biological response compare either single agent . The dose schedule dosing may modify base emerge safety , pharmacokinetic ( PK ) , pharmacodynamic ( PD ) data . The study conduct two part ; Part 1 Dose Escalation determine MTD RP2D Part 2 Expansion Cohort evaluate safety tolerability trametinib GSK2256098 RP2D determine clinical activity . Additionally , Part 1 Dose Escalation , additional subject malignant pleural mesothelioma ( MPM ) recruit dos consider tolerable order ass PD MPM subject dose ( Pharmacodynamic Cohort ) . The Expansion Cohort limit subject MPM progress intolerant first-line therapy .</brief_summary>
	<brief_title>A Dose Escalation Study Assess Safety GSK2256098 ( FAK Inhibitor ) Combination With Trametinib ( MEK Inhibitor ) Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Trametinib</mesh_term>
	<criteria>Inclusion Criteria Part 1 Subject Subjects measurable tumor may benefit treatment GSK2256098 trametinib . This include mesothelioma along tumor high likelihood MAPK pathway activation report medical literature . Part 2 Subject Histologically cytologically confirm diagnosis recurrent progressive , unresectable MPM measurable lesion . Part 1 Part 2 Subject Written inform consent provide . Males females &gt; =18 year age ( time consent obtain ) . Performance Status score 0 1 accord Eastern Cooperative Oncology Group ( ECOG ) scale . Able swallow retain orally administer study treatment . Women childbearing potential must negative serum pregnancy test within 7 day prior first dose study treatment agree use effective contraception per study protocol specification . Men female partner childbearing potential must either prior vasectomy agree use effective contraception per study protocol specification . Adequate organ system function define protocol Exclusion Criteria Mesotheliomas originate outside pleural cavity ( e.g. , peritoneal mesothelioma ) exclude Pharmacodynamic Cohort Part 1 Part 2 , permit Dose Escalation Cohorts Part 1 . Subjects leptomeningeal brain metastasis spinal cord compression . Use investigational anticancer drug within 28 day five halflives minimum duration 10 day prior therapy precede first dose GSK2256098/trametinib OR Chemotherapy within last 3 week ( 6 week prior nitrosourea mitomycin C ) OR major surgery , radiotherapy , immunotherapy within last 4 week . NOTE : Limited palliative radiation ( i.e. , duration typically &lt; 15 day ) last dose &gt; =6 week precede first dose combination treatment acceptable provide subject meet eligibility criterion radiotherapy port encompass measurable tumor . In addition , prophylactic radiation therapy site tumor biopsy ( per standard care ) current study prevent seed needle tract/biopsy acceptable require dose modification . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate GSK2256098 trametinib . Previous treatment GSK2256098 trametinib , well MEK FAK inhibitor . Current use prohibit medication require medication treatment . Current use warfarin therapeutic anticoagulation . NOTE : Low molecular weight heparin permit . PT/PTT must meet inclusion criterion . Presence active gastrointestinal disease , condition know interfere significantly absorption , distribution , metabolism , excretion drug . History evidence cardiovascular risk include follow : Left ventricle ejection fraction ( LVEF ) &lt; low limit normal ( LLN ) per local institutional practice ; A QT interval correct heart rate use Fredericia 's formula ( QTcF ) &gt; =480 msec ; History evidence current clinically significant uncontrolled arrhythmia ; Exception : Subjects control atrial fibrillation &gt; 30 day prior randomization eligible ; History acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty , stenting within 6 month prior randomization ; History evidence current &gt; = Class II congestive heart failure define New York Heart Association ; Treatment refractory hypertension define blood pressure systolic &gt; 140 millimeter mercury ( mmHg ) and/or diastolic &gt; 90 mmHg control antihypertensive therapy ; Patients intracardiac defibrillator permanent pacemaker ; Known cardiac metastasis ; Active interstitial lung disease pneumonitis . History current evidence / risk retinal vein occlusion ( RVO ) central serous retinopathy ( CSR ) : History RVO CSR , predispose factor RVO CSR ( e.g. , uncontrolled glaucoma ocular hypertension , uncontrolled systemic disease hypertension , diabetes mellitus , history hyperviscosity hypercoagulability syndrome ) ; Visible retinal pathology assess ophthalmic exam consider risk factor RVO CSR : Evidence new optic disc cupping , Evidence new visual field defect Intraocular pressure &gt; 21 mmHg Known Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) infection ( subject laboratory evidence clear HBV HCV infection permit ) . History another malignancy ( excludes nonmelanoma skin cancer ) . Exception : Subjects continuously diseasefree 3 year complete resection noninvasive primary cancer within 3 year enrollment . Consult GSK Medical Monitor unsure whether second malignancy meet requirement specify . Psychological , familial , sociological , geographical condition permit compliance protocol . Concurrent condition Investigator 's opinion would jeopardize compliance protocol . Nursing female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>pharmacodynamics</keyword>
	<keyword>MEK inhibitor</keyword>
	<keyword>Focal adhesion kinase inhibitor</keyword>
	<keyword>cancer</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>mesothelioma</keyword>
	<keyword>Phase 1</keyword>
</DOC>